Cancer Chemotherapy and Pharmacology

, Volume 14, Issue 3, pp 247–249 | Cite as

Beta-2-microglobulin excretion: An indicator of long term nephrotoxicity during cis-platinum treatment?

  • Peter Grundtvig Sørensen
  • Mogens H. Nissen
  • Steffen Groth
  • Mikael Rørth
Original Articles Beta-2-microglobulin and cis-platinum

Summary

To evaluate the value of beta-2-microglobulin as an indicator of acute and long-term cis-platinum-induced nephrotoxicity, 51Cr-EDTA clearance and serum concentration and urinary excretion of beta-2-microglobulin were measured in 18 patients treated with a regimen, including cis-platinum. Before treatment all values were within the normal range. During treatment 51Cr-EDTA clearance decreased from 108 to 90 ml/min/1.73 m2 (P<0.02). The decrease was irreversible, while a transient 2 to 5-fold increase in beta-2-microglobulin excretion in the urine was seen during treatment. Serum beta-2-microglobulin remained unchanged. The decrease in 51Cr-EDTA clearance was not correlated to either the peak increase in the beta-2-microglobulin excretion or to the time of occurrence of the peak (R=0.3). Thus, it is not possible to predict the long-term nephrotoxicity of cis-platinum by measuring the beta-2-microglobulin excretion during treatment.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cohen AI, Harberg J, Citrin DL (1981) Measurement of urinary beta-2-microglobulin in the detection of cisplatin nephrotoxicity. Cancer Treat Rep 65:1083Google Scholar
  2. 2.
    Cooper EH, Plesner T (1980) Beta-2-microglobulin review: Its relevance in clinical oncology. Med Pediatr Oncol 8:23Google Scholar
  3. 3.
    Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH (1978) Long-term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41:1274Google Scholar
  4. 4.
    Einhorn LH, Donohue J (1977) cis-Diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy, in disseminated testicular cancer. Am J Intern Med 87:293Google Scholar
  5. 5.
    Flemming JJ, Collis C, Peckham MJ (1979) Renal damage after cis-platinum. Lancet p 960Google Scholar
  6. 6.
    Frick GA, Ballentine R, Driever CW, Kramer WG (1979) Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum (II) administered with hydration and mannitol diuresis. Cancer Treat Rep 63:13Google Scholar
  7. 7.
    Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1977) The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362Google Scholar
  8. 8.
    Groth S, Aasted M (1981) 51Cr-EDTA clearance determined by one plasma sample. Clin Physiol 1:417Google Scholar
  9. 9.
    Hardaker WT, Stone RA, McCory R (1974) Platinum nephrotoxicity. Cancer 34:1030Google Scholar
  10. 10.
    Jensen KB (1967) Immunochemical determination of serum concentrations of albumin, IgG and IgM. In: Peters H (ed) Protides of the biological fluids, vol 14. Elsevier, Amsterdam, p 667Google Scholar
  11. 11.
    Jones BR, Bhalla RB, Mladek J, et al. (1980) Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther 27:557Google Scholar
  12. 12.
    Meijer S, Sleijer DTH, Mulder NH et al. (1983) Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma. Cancer 51:2035Google Scholar
  13. 13.
    Plesner T (1980) Immunochemical studies of human beta-2-microglobulin. Allergy 35:627Google Scholar
  14. 14.
    Prestayko AW, D'Aoust JC, Issell BF, Crooke ST (1979) Cisplatin. Cancer Teat Rep 6:17Google Scholar
  15. 15.
    Sørensen PG, Groth S, Rossing N (1983) The leakage of plasma albumin across small vessel walls during bleomycin treatment. Eur J Cancer Clin Oncol 19:29Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • Peter Grundtvig Sørensen
    • 1
    • 2
    • 3
  • Mogens H. Nissen
    • 1
    • 2
    • 3
  • Steffen Groth
    • 1
    • 2
    • 3
  • Mikael Rørth
    • 1
    • 2
    • 3
  1. 1.Department of Clinical PhysiologyThe Finsen InstituteCopenhagenDenmark
  2. 2.Department of Clinical ChemistryThe Finsen InstituteCopenhagenDenmark
  3. 3.Department of Chemotherapy R II-VThe Finsen InstituteCopenhagenDenmark

Personalised recommendations